1nhaler receives £1.5m in funding to develop new cardboard inhaler
Esme Needham | November 19, 2025 | News story | Research and Development | 1nhaler, asthma
1nhaler, a Scotland-based developer of drug delivery devices, has received £1.5m in seed funding for the development of its new pop-up cardboard dry powder inhaler (DPI).
Inhalable medicines are used not only for the treatment of asthma, but also of conditions such as COPD, influenza, anaphylaxis, epilepsy, depression and Parkinson’s. Inhalers are usually made from plastic and designed for multiple uses; 1nhaler’s DPI design, by contrast, is small, lightweight and disposable. It is made from eco-friendly cardboard and can be ‘popped up’ by the user to create a three-dimensional inhaler.
Although it is disposable, the new DPI’s cardboard construction is aimed towards sustainability, and carries a lower global warming potential than traditional plastic inhalers.
Derek Shaw, director of entrepreneurship and investment at Scottish Enterprise, said: “1nhaler is a great example of the kind of world-class innovation we want to see scale from Scotland. Their technology combines cutting-edge design with sustainability, addressing global healthcare needs while reducing environmental impact.”
The funding round, led by Archangels with support from Scottish Enterprise and BBB Investments, follows a prior funding round in 2023 which totalled £2m. It will enable 1nhaler to further develop the new product, which it hopes to submit a Marketing Authorisation Application for in late 2027. Additionally, 1nhaler has already established manufacturing partnerships with Upperton and Harro Höfliger for future large-scale manufacture of the product.
“This additional funding represents strong continued confidence in our technology platform and our progress towards commercialisation,” said Lisa McMyn, co-founder and CEO of 1nhaler. “Our platform has the potential to become the simplest, most convenient single-dose, disposable inhaler on the market, transforming the delivery of inhalable drugs without the cost and environmental impact of existing devices.”
Related Content
GSK shares positive results from phase 3 asthma trials
GSK has announced positive headline results from its phase 3 SWIFT-1 and SWIFT-2 trials, which …
GSK’s low carbon inhaler, Ventolin, progresses to phase 3 trials
GSK has announced that in 2024 it intends to start phase 3 trials of a …
Lupin Healthcare launches Beclu carbon neutral inhalers for asthma treatment
UK-based subsidiary of Lupin Limited, Lupin Healthcare, has announced the UK launch of its carbon …
